See how we capture >15K small molecule biomarkers per biosample in a single run, across thousands of samples.
See how we capture >15K small molecule biomarkers per biosample in a single run, across thousands of samples.
Now available on demand! Explore how small molecule biomarkers can drive greater understanding of autoimmune diseases.
Now available on demand! Explore the applications for small molecule biomarkers in cell & gene therapy development.
“Out of graduate school, Dr. Mohit Jain (co-founder and CEO of Sapient, but a university professor at the time) approached me with a fascinating problem. He had access to a biobank of human samples that, with current technology, would take the better part of a decade to analyze and wanted to know if I could… Continue reading The Future Is Now: Authority Magazine Interview with Sapient’s Jeramie Watrous
“I would argue that for nearly every common disease, there are multiple forms of the disease that have been amalgamated into one definition that all result in the same end pathology. Whether that end pathology is heart disease, Alzheimer’s disease, liver disease, lung disease, GI illness, renal disease, et cetera. Now, we know it to… Continue reading Futurati Podcast: Biomarkers and personalized medicine
The inherent heterogeneity in patient populations can often lead to variable drug response. We recently worked with a client who came to us after their Phase III clinical trial for a rare disease indication, consisting of several hundred participants, failed to reach its primary endpoint. We asked, can we identify a biomarker that indicates patients… Continue reading Discovery of a PD Biomarker to Predict Drug Response
Learn how we perform discovery screenings and then can translate key identified biomarkers into clinical assays.
August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, Sapient passed a rigorous evaluation process that involved an in-depth inspection of its clinical… Continue reading Sapient’s High Complexity CLIA Laboratory Receives Accreditation from the College of American Pathologists (CAP)
The PD-1 pathway has transformed the development of immunotherapies as a means to reawaken the immune system to target cancer cells. Clinically, however, there is a great deal of heterogeneity in the response to PD-1 based therapeutics across cancer patients, irrespective of the underlying tumor. There is some data to suggest that tumor burden mutational… Continue reading Discovery of PD-1 Pathway Biomarkers of Target Engagement
Watch the Livestream Recording | Presented by Bruker Watch the full recording of our recent lab tour showing how Sapient’s next-generation, ultra-high throughput rapid liquid chromatography-mass spectrometry (rLC-MS) platform leverages the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 to enable large-scale biomarker profiling. See how the systems perform nontargeted measurement of >15,000 circulating small molecule biomarkers per… Continue reading “Live from the Lab” at Sapient: On-Demand Virtual Lab Tour with Bruker
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
© 2024 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
